

# Michael H Davidson

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/2079960/michael-h-davidson-publications-by-year.pdf>

**Version:** 2024-04-25

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

108  
papers

5,070  
citations

35  
h-index

70  
g-index

112  
ext. papers

5,620  
ext. citations

4.1  
avg, IF

5.82  
L-index

#	Paper	IF	Citations
108	Left ventricular mass regression, all-cause and cardiovascular mortality in chronic kidney disease: a meta-analysis.. <i>BMC Nephrology</i> , <b>2022</b> , 23, 34	2.7	0
107	Targeting the cytoskeleton and extracellular matrix in cardiovascular disease drug discovery.. <i>Expert Opinion on Drug Discovery</i> , <b>2022</b> , 1-18	6.2	1
106	Recent advances and emerging therapies in management of dyslipidemias. <i>Trends in Cardiovascular Medicine</i> , <b>2021</b> , 31, 419-424	6.9	1
105	How I treat statin-associated side effects in an outpatient setting. <i>Future Cardiology</i> , <b>2021</b> , 17, 1249-1260.	6.3	4
104	Lipid measurements in the management of cardiovascular diseases: Practical recommendations a scientific statement from the national lipid association writing group. <i>Journal of Clinical Lipidology</i> , <b>2021</b> ,	4.9	6
103	Omega-3 fatty acid exposure with a low-fat diet in patients with past hypertriglyceridemia-induced acute pancreatitis; an exploratory, randomized, open-label crossover study. <i>Lipids in Health and Disease</i> , <b>2020</b> , 19, 117	4.4	0
102	Consensus Statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the Management of Dyslipidemia and Prevention of Cardiovascular Disease Algorithm - 2020 Executive Summary. <i>Endocrine Practice</i> , <b>2020</b> , 26, 1196-1224	3.2	27
101	The Role of Genetics in Cardiovascular Risk Reduction: Findings From a Single Lipid Clinic and Review of the Literature. <i>Cardiovascular Revascularization Medicine</i> , <b>2020</b> , 21, 200-204	1.6	1
100	The Effect of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibition on Sterol Absorption Markers in a Cohort of Real-World Patients. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , <b>2019</b> , 24, 54-61	2.6	3
99	Comparing remnant lipoprotein cholesterol measurement methods to evaluate efficacy of ezetimibe/statin vs statin therapy. <i>Journal of Clinical Lipidology</i> , <b>2019</b> , 13, 997-1007.e8	4.9	1
98	Evolution of Omega-3 Fatty Acid Therapy and Current and Future Role in the Management of Dyslipidemia. <i>Cardiology Clinics</i> , <b>2018</b> , 36, 277-285	2.5	3
97	Triglyceride-rich lipoprotein cholesterol (TRL-C): the ugly stepsister of LDL-C. <i>European Heart Journal</i> , <b>2018</b> , 39, 620-622	9.5	8
96	Omega-3 carboxylic acids in patients with severe hypertriglyceridemia: EVOLVE II, a randomized, placebo-controlled trial. <i>Journal of Clinical Lipidology</i> , <b>2018</b> , 12, 321-330	4.9	16
95	Advances in diagnosis and potential therapeutic options for familial chylomicronemia syndrome. <i>Expert Opinion on Orphan Drugs</i> , <b>2018</b> , 6, 141-149	1.1	4
94	How Genomics Is Personalizing the Management of Dyslipidemia and Cardiovascular Disease Prevention. <i>Current Cardiology Reports</i> , <b>2018</b> , 20, 138	4.2	3
93	Ω Polyunsaturated Fatty Acids and Cardiometabolic Health: Current Evidence, Controversies, and Research Gaps. <i>Advances in Nutrition</i> , <b>2018</b> , 9, 688-700	10	41
92	The burden of familial chylomicronemia syndrome: Results from the global IN-FOCUS study. <i>Journal of Clinical Lipidology</i> , <b>2018</b> , 12, 898-907.e2	4.9	26

91	Systemic Bioavailability and Dose Proportionality of Omega-3 Administered in Free Fatty Acid Form Compared With Ethyl Ester Form: Results of a Phase 1 Study in Healthy Volunteers. <i>European Journal of Drug Metabolism and Pharmacokinetics</i> , <b>2017</b> , 42, 815-825	2.7	9
90	No Effect of Omega-3 Carboxylic Acids on Pharmacokinetics/Pharmacodynamics of Warfarin or on Platelet Function When Co-administered with Acetylsalicylic Acid: Results of Two Phase I Studies in Healthy Volunteers. <i>American Journal of Cardiovascular Drugs</i> , <b>2017</b> , 17, 251-260	4	1
89	Assessment of pharmacokinetic interaction between omega-3 carboxylic acids and the statins rosuvastatin and simvastatin: Results of 2 phase I studies in healthy volunteers. <i>Journal of Clinical Lipidology</i> , <b>2017</b> , 11, 739-748	4.9	2
88	The burden of familial chylomicronemia syndrome: interim results from the IN-FOCUS study. <i>Expert Review of Cardiovascular Therapy</i> , <b>2017</b> , 15, 415-423	2.5	34
87	Development and Content Validity of the Statin Experience Assessment Questionnaire (SEAQ) . <i>Patient</i> , <b>2017</b> , 10, 321-334	3.7	9
86	Using Discordance in Monozygotic Twins to Understand Causality of Cardiovascular Disease Risk Factors. <i>JAMA Internal Medicine</i> , <b>2016</b> , 176, 1530	11.5	1
85	The effect of omega-3 carboxylic acids on apolipoprotein CIII-containing lipoproteins in severe hypertriglyceridemia. <i>Journal of Clinical Lipidology</i> , <b>2016</b> , 10, 1442-1451.e4	4.9	16
84	The future of n-3 polyunsaturated fatty acid therapy. <i>Current Opinion in Lipidology</i> , <b>2016</b> , 27, 570-578	4.4	13
83	Large high-density lipoprotein particle number is independently associated with microvascular function in patients with well-controlled low-density lipoprotein concentration: A vasodilator stress magnetic resonance perfusion study. <i>Journal of Clinical Lipidology</i> , <b>2016</b> , 10, 314-22	4.9	4
82	Update on PCSK9 therapies for the treatment of dyslipidemia. <i>Expert Review of Endocrinology and Metabolism</i> , <b>2016</b> , 11, 87-95	4.1	2
81	Changing characteristics of statin-related cIMT trials from 1988 to 2006. <i>Atherosclerosis</i> , <b>2016</b> , 246, 121-9.1	3.1	2
80	Time-related trends in variability of cIMT changes in statin trials. <i>Data in Brief</i> , <b>2016</b> , 6, 530-41	1.2	
79	The Risk of Hepatotoxicity, New Onset Diabetes and Rhabdomyolysis in the Era of High-Intensity Statin Therapy: Does Statin Type Matter?. <i>Progress in Cardiovascular Diseases</i> , <b>2016</b> , 59, 145-152	8.5	15
78	Underappreciated opportunities for high-density lipoprotein particles in risk stratification and potential targets of therapy. <i>Cardiovascular Drugs and Therapy</i> , <b>2015</b> , 29, 41-50	3.9	10
77	Therapeutic ultrasound: Increased HDL-Cholesterol following infusions of acoustic microspheres and apolipoprotein A-I plasmids. <i>Atherosclerosis</i> , <b>2015</b> , 241, 92-9	3.1	10
76	Beta-2 Agonism: A Potential Therapeutic Target for Dyslipidemia. <i>EBioMedicine</i> , <b>2015</b> , 2, 284	8.8	
75	Role of Ezetimibe in Lipid-Lowering and Cardiovascular Disease Prevention. <i>Current Atherosclerosis Reports</i> , <b>2015</b> , 17, 72	6	10
74	Effects of omega-3 carboxylic acids on lipoprotein particles and other cardiovascular risk markers in high-risk statin-treated patients with residual hypertriglyceridemia: a randomized, controlled, double-blind trial. <i>Lipids in Health and Disease</i> , <b>2015</b> , 14, 98	4.4	38

73	Management of lipoprotein X and its complications in a patient with primary sclerosing cholangitis. <i>Clinical Lipidology</i> , <b>2015</b> , 10, 305-312		9
72	Statin intolerance - an attempt at a unified definition. Position paper from an International Lipid Expert Panel. <i>Archives of Medical Science</i> , <b>2015</b> , 11, 1-23	2.9	252
71	Comparison of the lipid-lowering effects of pitavastatin 4 mg versus pravastatin 40 mg in adults with primary hyperlipidemia or mixed (combined) dyslipidemia: a Phase IV, prospective, US, multicenter, randomized, double-blind, superiority trial. <i>Clinical Therapeutics</i> , <b>2014</b> , 36, 1211-22	3.5	21
70	Effects of fenofibric acid on carotid intima-media thickness in patients with mixed dyslipidemia on atorvastatin therapy: randomized, placebo-controlled study (FIRST). <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , <b>2014</b> , 34, 1298-306	9.4	55
69	Omega-3 free fatty acids for the treatment of severe hypertriglyceridemia: the EpanoVa fOR Lowering Very high triglyceridEs (EVOLVE) trial. <i>Journal of Clinical Lipidology</i> , <b>2014</b> , 8, 94-106	4.9	163
68	Overcoming toxicity and side-effects of lipid-lowering therapies. <i>Best Practice and Research in Clinical Endocrinology and Metabolism</i> , <b>2014</b> , 28, 439-52	6.5	31
67	Addition of omega-3 carboxylic acids to statin therapy in patients with persistent hypertriglyceridemia. <i>Expert Review of Cardiovascular Therapy</i> , <b>2014</b> , 12, 1045-54	2.5	5
66	Combination therapy with statins: who benefits?. <i>Endocrinology and Metabolism Clinics of North America</i> , <b>2014</b> , 43, 993-1006	5.5	1
65	Genetics and causality of triglyceride-rich lipoproteins in atherosclerotic cardiovascular disease. <i>Journal of the American College of Cardiology</i> , <b>2014</b> , 64, 2525-40	15.1	149
64	Potential impact of dipeptidyl peptidase-4 inhibitors on cardiovascular pathophysiology in type 2 diabetes mellitus. <i>Postgraduate Medicine</i> , <b>2014</b> , 126, 56-65	3.7	10
63	Use of microsomal triglyceride transfer protein inhibitors in patients with homozygous familial hypercholesterolemia: translating clinical trial experience into clinical practice. <i>Reviews in Cardiovascular Medicine</i> , <b>2014</b> , 15, 1-10	3.9	2
62	Risk of hospitalized rhabdomyolysis associated with lipid-lowering drugs in a real-world clinical setting. <i>Journal of Clinical Lipidology</i> , <b>2013</b> , 7, 102-8	4.9	28
61	A highly bioavailable omega-3 free fatty acid formulation improves the cardiovascular risk profile in high-risk, statin-treated patients with residual hypertriglyceridemia (the ESPRIT trial). <i>Clinical Therapeutics</i> , <b>2013</b> , 35, 1400-11.e1-3	3.5	81
60	The efficacy of colesevlam HCl in the treatment of heterozygous familial hypercholesterolemia in pediatric and adult patients. <i>Clinical Therapeutics</i> , <b>2013</b> , 35, 1247-52	3.5	12
59	Omega-3 fatty acids: new insights into the pharmacology and biology of docosahexaenoic acid, docosapentaenoic acid, and eicosapentaenoic acid. <i>Current Opinion in Lipidology</i> , <b>2013</b> , 24, 467-74	4.4	71
58	Measurement of LDL-C after treatment with the CETP inhibitor anacetrapib. <i>Journal of Lipid Research</i> , <b>2013</b> , 54, 467-72	6.3	41
57	Steady-state bioavailability of prescription omega-3 on a low-fat diet is significantly improved with a free fatty acid formulation compared with an ethyl ester formulation: the ECLIPSE II study. <i>Vascular Health and Risk Management</i> , <b>2013</b> , 9, 563-73	4.4	63
56	Study design, rationale, and baseline characteristics: evaluation of fenofibric acid on carotid intima-media thickness in patients with type IIb dyslipidemia with residual risk in addition to atorvastatin therapy (FIRST) trial. <i>Cardiovascular Drugs and Therapy</i> , <b>2012</b> , 26, 349-58	3.9	13

55	A novel omega-3 free fatty acid formulation has dramatically improved bioavailability during a low-fat diet compared with omega-3-acid ethyl esters: the ECLIPSE (Epanova(®) compared to Lovaza(®) in a pharmacokinetic single-dose evaluation) study. <i>Journal of Clinical Lipidology</i> , <b>2012</b> , 6, 573-84	4.9	139
54	Cardio-diabetes: special considerations for the patient with diabetes and cardiovascular disease. Introduction. <i>American Journal of Cardiology</i> , <b>2012</b> , 110, 1B-3B	3	
53	Cardiovascular risk factors in a patient with diabetes mellitus and coronary artery disease: therapeutic approaches to improve outcomes: perspectives of a preventive cardiologist. <i>American Journal of Cardiology</i> , <b>2012</b> , 110, 43B-49B	3	24
52	Focusing on high-density lipoprotein for coronary heart disease risk reduction. <i>Cardiology Clinics</i> , <b>2011</b> , 29, 105-22	2.5	8
51	Predictors of anterior and posterior wall carotid intima media thickness progression in men and women at moderate risk of coronary heart disease. <i>Journal of Clinical Lipidology</i> , <b>2011</b> , 5, 141-151	4.9	17
50	Clinical utility of inflammatory markers and advanced lipoprotein testing: advice from an expert panel of lipid specialists. <i>Journal of Clinical Lipidology</i> , <b>2011</b> , 5, 338-67	4.9	201
49	The role of cardiologists in the management of patients with diabetes is evolving owing to the close relationship between diabetes and CAD. Introduction. <i>American Journal of Cardiology</i> , <b>2011</b> , 108, 1B-2B	3	4
48	Cardiovascular effects of glucagonlike peptide-1 agonists. <i>American Journal of Cardiology</i> , <b>2011</b> , 108, 33B-41B	3	56
47	Novel developments in omega-3 fatty acid-based strategies. <i>Current Opinion in Lipidology</i> , <b>2011</b> , 22, 437-444	4.4	25
46	Pioglitazone versus glimepiride on coronary artery calcium progression in patients with type 2 diabetes mellitus: a secondary end point of the CHICAGO study. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , <b>2010</b> , 30, 1873-6	9.4	6
45	Counterpoint: Low-density lipoprotein cholesterol goals in patients with diabetes are adequately based on evidence. <i>Journal of Clinical Lipidology</i> , <b>2010</b> , 4, 72-3; discussion 74	4.9	
44	ACAT inhibition and progression of carotid atherosclerosis in patients with familial hypercholesterolemia: the CAPTIVATE randomized trial. <i>JAMA - Journal of the American Medical Association</i> , <b>2009</b> , 301, 1131-9	27.4	114
43	Efficacy and tolerability of atorvastatin/fenofibrate fixed-dose combination tablet compared with atorvastatin and fenofibrate monotherapies in patients with dyslipidemia: a 12-week, multicenter, double-blind, randomized, parallel-group study. <i>Clinical Therapeutics</i> , <b>2009</b> , 31, 2824-38	3.5	35
42	Novel targets that affect high-density lipoprotein metabolism: the next frontier. <i>American Journal of Cardiology</i> , <b>2009</b> , 104, 52E-7E	3	13
41	Apolipoprotein measurements: is more widespread use clinically indicated?. <i>Clinical Cardiology</i> , <b>2009</b> , 32, 482-6	3.3	63
40	Hypercholesterolemia treatment patterns and low-density lipoprotein cholesterol monitoring in patients with a diagnosis of atherosclerosis in clinical practice. <i>American Journal of Medicine</i> , <b>2009</b> , 122, S51-9	2.4	6
39	Medical management of patients before the incidence of a cardiovascular event. <i>Journal of Clinical Lipidology</i> , <b>2009</b> , 3, 315-21	4.9	2
38	Niacin therapy: an evolving paradigm for the management of mixed dyslipidemia and low high-density lipoprotein cholesterol. Introduction. <i>American Journal of Cardiology</i> , <b>2008</b> , 101, 1B-2B	3	1

37	Niacin use and cutaneous flushing: mechanisms and strategies for prevention. <i>American Journal of Cardiology</i> , <b>2008</b> , 101, 14B-19B	3	63
36	Consensus panel recommendation for incorporating lipoprotein-associated phospholipase A2 testing into cardiovascular disease risk assessment guidelines. <i>American Journal of Cardiology</i> , <b>2008</b> , 101, 51F-57F	3	110
35	A review of the current status of the management of mixed dyslipidemia associated with diabetes mellitus and metabolic syndrome. <i>American Journal of Cardiology</i> , <b>2008</b> , 102, 19L-27L	3	23
34	Retrospective comparison of the effectiveness of a fenofibrate 145 mg formulation compared with the standard 160 mg tablet. <i>Clinical Drug Investigation</i> , <b>2008</b> , 28, 615-23	3.2	4
33	Interrupting bile-acid handling and lipid and glucose control: Effects of colesevelam on glucose levels. <i>Journal of Clinical Lipidology</i> , <b>2008</b> , 2, S29-33	4.9	5
32	Omega-3 fatty acids and coronary heart disease risk: clinical and mechanistic perspectives. <i>Atherosclerosis</i> , <b>2008</b> , 197, 12-24	3.1	417
31	Prescription omega-3 fatty acids and their lipid effects: physiologic mechanisms of action and clinical implications. <i>Expert Review of Cardiovascular Therapy</i> , <b>2008</b> , 6, 391-409	2.5	171
30	Increased high-density lipoprotein cholesterol predicts the pioglitazone-mediated reduction of carotid intima-media thickness progression in patients with type 2 diabetes mellitus. <i>Circulation</i> , <b>2008</b> , 117, 2123-30	16.7	106
29	Omega-3 fatty acid concentrates in the treatment of moderate hypertriglyceridemia. <i>Expert Opinion on Pharmacotherapy</i> , <b>2008</b> , 9, 1237-48	4	63
28	Is LDL-C passed its prime? The emerging role of non-HDL, LDL-P, and ApoB in CHD risk assessment. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , <b>2008</b> , 28, 1582-3	9.4	15
27	Is ezetimibe/simvastatin no better than simvastatin alone? Lessons learned and clinical implications. <i>Cleveland Clinic Journal of Medicine</i> , <b>2008</b> , 75, 479-82, 486-8, 490-1	2.8	6
26	Safety of aggressive lipid management. <i>Journal of the American College of Cardiology</i> , <b>2007</b> , 49, 1753-62	15.1	123
25	Global risk management in patients with type 2 diabetes mellitus. <i>American Journal of Cardiology</i> , <b>2007</b> , 99, 41B-50B	3	31
24	Safety considerations with fibrate therapy. <i>American Journal of Cardiology</i> , <b>2007</b> , 99, 3C-18C	3	279
23	High-density lipoprotein metabolism: potential therapeutic targets. <i>American Journal of Cardiology</i> , <b>2007</b> , 100, n32-40	3	50
22	Targeting high-density lipoprotein cholesterol in the management of cardiovascular disease. <i>The American Heart Hospital Journal</i> , <b>2007</b> , 5, 210-6		4
21	Efficacy and tolerability of adding prescription omega-3 fatty acids 4 g/d to simvastatin 40 mg/d in hypertriglyceridemic patients: an 8-week, randomized, double-blind, placebo-controlled study. <i>Clinical Therapeutics</i> , <b>2007</b> , 29, 1354-67	3.5	327
20	Rosuvastatin in elderly patients. <i>Drugs and Aging</i> , <b>2007</b> , 24, 933-44	4.7	6

19	The use of colesvelam hydrochloride in the treatment of dyslipidemia: a review. <i>Expert Opinion on Pharmacotherapy</i> , <b>2007</b> , 8, 2569-78	4	28
18	Overview of prevention and treatment of atherosclerosis with lipid-altering therapy for pharmacy directors. <i>American Journal of Managed Care</i> , <b>2007</b> , 13 Suppl 10, S260-9	2.1	4
17	Striated muscle safety of ezetimibe/simvastatin (Vytorin). <i>American Journal of Cardiology</i> , <b>2006</b> , 97, 223-8	3	41
16	Statin safety: an appraisal from the adverse event reporting system. <i>American Journal of Cardiology</i> , <b>2006</b> , 97, 32C-43C	3	83
15	Statin safety: an assessment using an administrative claims database. <i>American Journal of Cardiology</i> , <b>2006</b> , 97, 61C-68C	3	97
14	Final conclusions and recommendations of the National Lipid Association Statin Safety Assessment Task Force. <i>American Journal of Cardiology</i> , <b>2006</b> , 97, 89C-94C	3	310
13	Statin/fibrate combination in patients with metabolic syndrome or diabetes: evaluating the risks of pharmacokinetic drug interactions. <i>Expert Opinion on Drug Safety</i> , <b>2006</b> , 5, 145-56	4.1	73
12	New concepts in dyslipidemia in the metabolic syndrome and diabetes. <i>Metabolic Syndrome and Related Disorders</i> , <b>2006</b> , 4, 299-314	2.6	2
11	Differences between clinical trial efficacy and real-world effectiveness. <i>American Journal of Managed Care</i> , <b>2006</b> , 12, S405-11	2.1	32
10	Management of dyslipidemia in patients with complicated metabolic syndrome. <i>American Journal of Cardiology</i> , <b>2005</b> , 96, 22E-25E	3	24
9	Reducing residual risk for patients on statin therapy: the potential role of combination therapy. <i>American Journal of Cardiology</i> , <b>2005</b> , 96, 3K-13K; discussion 34K-35K	3	58
8	Considerations in the treatment of dyslipidemia associated with chronic kidney failure and renal transplantation. <i>Preventive Cardiology</i> , <b>2005</b> , 8, 244-9		9
7	Lipid responses to a dietary docosahexaenoic acid supplement in men and women with below average levels of high density lipoprotein cholesterol. <i>Journal of the American College of Nutrition</i> , <b>2005</b> , 24, 189-99	3.5	54
6	Comparative effects of lipid-lowering therapies. <i>Progress in Cardiovascular Diseases</i> , <b>2004</b> , 47, 73-104	8.5	83
5	Biologic therapies for dyslipidemia. <i>Current Atherosclerosis Reports</i> , <b>2004</b> , 6, 69-72	6	5
4	Rosuvastatin safety: lessons from the FDA review and post-approval surveillance. <i>Expert Opinion on Drug Safety</i> , <b>2004</b> , 3, 547-57	4.1	60
3	Combination therapy in the management of complex dyslipidemias. <i>Current Opinion in Lipidology</i> , <b>2004</b> , 15, 423-31	4.4	22
2	Reducing cardiovascular risk: trends in risk, risk assessment, and cholesterol management. <i>Postgraduate Medicine</i> , <b>2004</b> , 116, 7-12	3.7	1

- 1 Colesevelam hydrochloride (cholestagel): a new, potent bile acid sequestrant associated with a low incidence of gastrointestinal side effects. *Archives of Internal Medicine*, **1999**, 159, 1893-900